It has been a tough year for the small biotech investorAfter a nice rise to start the year, the sector significantly has underperformed the overall market since around mid-February, as seen in the SPDR S&P Biotech ETF (XBI) . Given the large declines in so many small biotech and biopharma names in 2021, tax-loss selling is a headwind investors wil...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.